- Taiwan
- /
- Healthcare Services
- /
- TWSE:4104
Excelsior Medical Second Quarter 2024 Earnings: EPS: NT$1.42 (vs NT$1.11 in 2Q 2023)
Excelsior Medical (TWSE:4104) Second Quarter 2024 Results
Key Financial Results
- Revenue: NT$2.16b (up 6.8% from 2Q 2023).
- Net income: NT$220.4m (up 27% from 2Q 2023).
- Profit margin: 10% (up from 8.6% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: NT$1.42 (up from NT$1.11 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Excelsior Medical shares are up 5.5% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 1 warning sign for Excelsior Medical you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Excelsior Medical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:4104
Excelsior Medical
Sells medical supplies and equipment, medicines, and home medical devices in Taiwan, Hong Kong, the Philippines, and Malaysia.
Flawless balance sheet, good value and pays a dividend.